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INTRODUCTION
The cryptic t(12;21)(p13;q22) translocation was first descri-
bed in 1995 and is recognised as the most common structural 
chromosomal abnormality in paediatric B-cell precursor 
acute lymphoblastic leukaemia (BCP-ALL) occurring in 
~25% of children diagnosed with ALL.1,2 On the contrary, 
it is only observed in 1-4.4% of adult BCP-ALL.3 The translo-
cation gives rise to the fusion of Runt-related transcription 
factor 1 (RUNX1; formerly known as AML1) and ETS variant 
6 (ETV6; formerly known as TEL). This rearrangement is 
not detectable by conventional cytogenetic analysis as the 
G-banding pattern and size of the translocated regions 
between chromosome 12 and 21 are identical. Nevertheless, 
ETV6/RUNX1-positive BCP-ALL patients can easily be iden-
tified by fluorescence in situ hybridisation (FISH) and/or 
reverse transcription polymerase chain reaction (RT-PCR) 
analysis.3,4
The identification of ETV6/RUNX1 genomic sequences in 
neonatal blood spots and the fact that monozygotic twin 
pairs with concordant leukaemia share the exact same fusion 
gene sequence and unique genomic breakpoints, clearly 
suggests that this translocation can originate in utero.5 How-
ever, the low concordance rate in monozygotic twins (around 
5–10%), a prolonged postnatal latency between fusion for-
mation and disease presentation (up to fourteen years) and 
the presence of this fusion protein in cord blood at a higher 
frequency than the risk of developing the corresponding 
leukaemia, hints towards the fact that this translocation 
per se cannot induce overt leukaemia.6 Malignant progression 
depends on the acquisition of additional oncogenic, postnatal 
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genetic events.5,7,8 This concept was further confirmed using 
transplantation of bone marrow (BM) cells expressing the 
ETV6/RUNX1 fusion protein in a mouse model, where the 
ETV6/RUNX1 expression affected the normal haemato- 
poietic differentiation. Although the impaired haematopoietic 
differentiation led to the in vivo accumulation and persistence 
of B-cell progenitors and an increased self-renewal capacity, 
no leukaemia induction was observed during an observation 
period of over one year.9 
During lymphocyte development, immunoglobulin and T-cell 
receptor genes undergo somatic DNA rearrangements.10 This 
process is mediated by recombination-activating gene pro-
teins, such as RAG1 and RAG2, which recognise and bind 
recombination signal sequences (RSSs) that are located ad- 
jacent to the site of recombination. Notably, off-target RAG 
activity is an important driver of leukaemia, as exemplified 
by the frequent identification of RSS sites in close proximity 
of the genomic breakpoints of somatic deletions in human 
leukaemias.11-14 Similarly, aberrant RAG recombinase activity 
has also been identified as a dominant mechanism of tumour 
suppressor inactivation as secondary genetic events in ETV6/
RUNX1-positive BCP-ALL.15 
Commonly observed genetic alterations in the ETV6/RUNX1 
rearranged leukaemias include deletions of transcription 
factor genes  (such as PAX5, EBF1 or the wild-type copy of 
ETV6), cell cycle regulators (e.g. CDKN2A), recombination- 
activating enzymes (e.g. RAG1 or RAG2), lymphoid signalling 
molecules (e.g. BTLA, CD200 or TOX), alterations of tran-
scriptional co-activators (e.g. TBL1XR1), the glucocorticoid 
receptor NR3C1 and the apoptosis regulator BTG1.15-19
Although this BCP-ALL subtype is generally associated with 
a good prognosis with event-free survival rates approaching 
90% with contemporary treatment protocols, late relapses 
and resistance to chemotherapy do occur.20-22 
The late occurrence of relapse, together with clonal variation 
between initial and relapse leukaemias suggests that ETV6/
RUNX1-expressing pre-leukaemia sub-clones, which are 
not fully malignant at initial diagnosis, resist treatment 
and acquire additional genomic aberrations, which may be 
necessary for the manifestation of relapse.23-25 Genome-wide 
copy number analysis of matched diagnosis and relapse 
leukaemias, revealed particular alterations exclusively present 
or more abundant at relapse such as deletions of IKZF1, 
EBF1, CDKN2A, NR3C1 and NR3C2 genes, which might be 
either predictive or characteristic of relapse.25 
MOLECULAR STRUCTURE AND FUNCTION 
OF ETV6/RUNX1 
RUNX1
RUNX1 is located at chromosome 21q22.12 (Chr 21: 
34,787,801-36,004,667 reverse strand GRCh38) and encodes 
the α-subunit of the core-binding factor (CBFα). The RUNX1 
protein consists of two large functional domains: the highly 
conserved Runt domain which mediates both DNA binding 
and heterodimerization with the β-subunit (CBFβ) and the 
distal transactivation domain (Figure 1). The RUNX1 protein 
FIGURE 1. Schematic presentation of full-length ETV6, RUNX1 and ETV6/RUNX1 proteins.26 Arrows indicate fusion points 
between ETV6 and RUNX1 sequences. Amino acids that border the key functional domains are numbered with number 1 
corresponding to the first methionine. Adapted with permission from Macmillan Publishers Ltd: Oncogene, doi:10.1038/
sj.onc.1207672, copyright 2004.
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is a transcription factor with activating and repressing abili-
ties depending on recruitment of p300 or mSin3A/HDAC, 
respectively. The latter is a multi-protein co-repressor complex 
known to silence gene expression by deacetylating histones. 
Its association with these cofactors may also be dependent 
on the regulatory region of RUNX1 target genes and/or 
cell context (Figure 2A).26 Homozygous disruption of RUNX1 
activity in mice (RUNX1-/-) result in mid-gestation embryonic 
lethality and affects all definitive haematopoietic lineages 
indicating that this transcription factor is a master regulator 
for the formation of definitive haematopoietic stem cells 
during haematopoietic development.27 
ETV6
ETV6 is located at chromosome 12p13.2 (Chr 12: 
11,649,854-11,895,402 forward strand GRCh38) and enco-
des a member of the Ets family of transcription factors 
harbouring different functional domains such as an N-ter-
minally located oligomerisation pointed domain (PD) (also 
known as SAM or HLH domain), a central repression domain 
and a c-terminal ETS domain which mediates DNA binding 
(Figure 1).26 While RUNX1 is capable of either activating or 
repressing its target genes, ETV6 is generally considered to act 
as a transcriptional repressor. ETV6 protein localisation is 
confined to both nucleus and cytoplasm whereas RUNX1 is 
found only in the nucleus. ETV6 knockout in mice (ETV6-/-) 
is embryonic lethal, due to defects in yolk sac angiogenesis. 
Moreover, in mouse chimeras, which were constructed by 
injection of neoR-ETV6-/- embryonic stem cells in wild type 
blastocysts, low numbers of ETV6-/- haematopoietic proge- 
nitor cells detected in the BM suggest that ETV6 is required 
for homing of haematopoietic progenitors cells to the BM.28
ETV6/RUNX1 FUSION
Rearrangement of RUNX1 and ETV6 genes with multiple 
partners has been found in different types of lymphoid and 
myeloid leukaemias.29 However, the only known transloca- 
tion involving RUNX1 in BCP-ALL is the t(12;21)(p13;q22) 
(ETV6/RUNX1).30 This fusion gene encodes a chimeric tran-
scription factor which comprises the N-terminal ETV6 
sequence containing the Pointed/SAM and the central 
repression domain, and nearly the entire RUNX1 sequence 
with all known functional regions (Figure 1).1,2 The ETV6 
moiety of the fusion protein is responsible for the recruitment 
FIGURE 2. Molecular mechanism of wild type RUNX1 and ETV6/RUNX1.26 The transcription factor RUNX1 either activates 
or represses its target genes by recruitment of p300 or mSin3A/HDAC, respectively (A). By contrast, the abilities of the 
ETV6 moiety of ETV6/RUNX1 to recruit and bind to nuclear receptor corepressor/HDAC complex (N-CoR) and mSin3A allow 
formation of a very stable repressor complex (B). Adapted with permission from Macmillan Publishers Ltd: Oncogene, doi: 
10.1038/sj.onc.1207672, copyright 2004.
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of the nuclear receptor corepressor/HDAC complex (N-CoR) 
and other corepressor complexes including SMRT and 
mSin3A. Given that the fusion protein only possesses the 
DNA binding domain of RUNX1, it would be able to bind to 
the promoter and enhancer regions of RUNX1 target genes 
and repressing transcription of these genes (Figure 2B).31,32 
Using in vitro promoter-reporter assays, this hypothesis was 
confirmed as illustrated by the ability of ETV6/RUNX1 fusion 
protein to repress the regulatory regions of haematopoietic- 
specific genes. In addition, the histone deacetylase inhibitor 
Trichostatin A could rescue the observed repression.33,34
The ETV6 domain, encoded in the fusion protein, confers the 
ability for homo- or oligomerisation, allowing simultaneous 
and high affinity binding to multiple RUNX1 DNA-binding 
sites present in target-gene promoters.26 In addition, the 
fusion might hamper normal ETV6 transcriptional regulation 
through dimerization with, and thus sequestering wild type 
ETV6 and/or regulatory cofactors.35,36 
In vivo experiments using transplantation of BM cells with 
ETV6/RUNX1-expressing vectors in a mouse model showed 
that the ETV6/RUNX1 fusion protein impairs the normal 
haematopoietic development and differentiation program of 
B-lymphocytes resulting in accumulation of early B-cell pro-
genitors. Remarkably, the impact of ETV6/RUNX1 expression 
appears to be selective for B lymphoid lineages since no 
block in differentiation of other lineages was observed.9,37 
PERTURBED PATHWAYS IN ETV6/RUNX1-
POSITIVE BCP-ALL
Genome-wide transcriptome profiling has provided new 
insights into the mechanisms driving the development of 
ETV6/RUNX1 leukaemias. Studies comparing ETV6/RUNX1- 
positive and negative patients or cell lines revealed aberrant 
expression of genes involved in differentiation, apoptosis, 
signal transduction, PI3K/AKT/mTOR signalling and immune 
responses.38-40
Several of these findings were subsequently validated in vitro 
using ETV6/RUNX1-positive cell line models, such as REH 
and AT-2. For example, down-regulation of the fusion pro-
duct, resulted in a clear inhibition of the PI3K/AKT/mTOR 
signal pathway, suggesting that this signalling cascade is 
truly involved in the pathogenesis of ETV6/RUNX1-positive 
childhood leukaemia.38,39 Given the central role of the PI3K/
AKT/mTOR signalling pathway in many cellular activities 
critical for neoplastic behavior, it is likely that its aberrant 
activation is not only essential for initiation, but also for the 
maintenance of ETV6/RUNX1-positive leukaemias.41,42 
In addition, the role of this fusion protein in B-cell differen-
tiation, cell survival and cell renewal capacity was further 
confirmed by in vivo experiments. The ability of ETV6/
RUNX1 to block B-cell differentiation through down-regu- 
lation of the IRF3-IFNα/β pathway was demonstrated in 
mouse and human primary haematopoietic precursor cells, 
which was rescued by treatment of ETV6/RUNX1 expressing 
cells with IFNα/β.43 The repopulation capacity of ETV6/
RUNX1-supressed REH cells in xenotransplantation NOD/
SCID mouse models was diminished as these mice developed 
leukaemia significantly later than the mice which received 
the negative control cells.38,39 Furthermore, an inhibitory 
impact of ETV6/RUNX1 on the response to TGF-beta was 
shown in both murine and human model systems. The cells 
expressing the ETV6/RUNX1 fusion protein showed reduced 
sensitivity to TGFβ-mediated inhibition of proliferation.44 
These studies provided additional evidence for the role of 
the ETV6/RUNX1 fusion gene in sustaining the leukaemia 
process.
UNIQUE LONG NON-CODING RNA 
EXPRESSION SIGNATURE IN ETV6/
RUNX1-DRIVEN BCP-ALL
Overwhelming evidence indicates that long non-coding 
RNAs (lncRNA) have essential roles in tumorigenesis. Never-
theless, their role in the molecular pathogenesis of paediatric 
BCP-ALL has not been extensively explored. In a recent 
comprehensive analysis of the lncRNA transcriptome in 
ETV6/RUNX1-positive BCP-ALL, a unique ETV6/RUNX1 
lncRNA signature was established and the transcriptional 
and phenotypic consequences of lncRNA modulation in 
the context of ETV6/RUNX1 rearranged leukaemia was ana-
lysed. This set of experiments revealed that lnc-NKX2-3-1, 
lnc-TIMM21-5, lnc-ASTN1-1 and lnc-RTN4R-1 were truly 
regulated by the oncogenic fusion protein. Moreover, sus-
tained inactivation of lnc-RTN4R-1 in ETV6/RUNX1 positive 
cells reduced cell viability and caused profound changes in 
gene expression. Hence, lnc-RTN4R-1 was identified as an 
lncRNA that might be functionally implicated in the biology 
of this prevalent subtype of human leukaemia.45
CONCLUSION
The ETV6/RUNX1 rearrangement, the most common gene-
tic abnormality in childhood BCP-ALL, is usually associated 
with a favourable outcome. Late relapses and chemotherapy 
resistance remain a problem, indicating the need for identi-
fication of additional prognostic markers in this subtype 
of BCP-ALL. Genome-wide profiling studies have shown 
that ETV6/RUNX1-positive leukaemias are characterised by 
a unique coding and non-coding gene expression signature 
with differential expression of genes involved in differentia-
tion, apoptosis, signal transduction and immune response. 
Overall, these data provide new insights into the mechanisms 
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driving the development of ETV6/RUNX1 leukaemias, which 
may lead to the development of novel therapeutic strategies. 
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